Valuation: Axogen, Inc.

Market Cap 2.27B 1.97B 1.84B 1.69B 3.19B 216B 3.24B 21.71B 8.5B 108B 8.52B 8.34B 356B P/E 2026 *
-92.6x
P/E 2027 * 721x
Enterprise Value 2.27B 1.97B 1.84B 1.69B 3.19B 216B 3.24B 21.71B 8.5B 108B 8.52B 8.34B 356B EV / Sales 2026 *
8.12x
EV / Sales 2027 * 6.85x
Free-Float
96.54%
Yield 2026 *
-
Yield 2027 * -
1 day+9.10%
1 week+11.30%
Current month+8.48%
1 month-0.39%
3 months+7.41%
6 months+30.05%
Current year+39.90%
1 week 38.31
Extreme 38.31
46.15
1 month 38.23
Extreme 38.23
46.95
Current year 27.54
Extreme 27.54
46.95
1 year 12.38
Extreme 12.385
46.95
3 years 3.45
Extreme 3.45
46.95
5 years 3.45
Extreme 3.45
46.95
10 years 3.45
Extreme 3.45
56.85
Manager TitleAgeSince
Chief Executive Officer 66 08/08/2024
Director of Finance/CFO 42 11/05/2025
Chief Operating Officer 65 09/01/2025
Director TitleAgeSince
Director/Board Member 65 31/08/2016
Director/Board Member 58 14/05/2019
Chairman 70 08/08/2024
Date Insider Type Main position Quantity % Market Cap.
26/02/26 Free

Chief Executive Officer

98,000 0.1955%
26/02/26 Free

Executive/Senior Manager

78,758 0.1571%
26/02/26 Free

Compliance Officer

92,460 0.1845%
Change 5-day change 1-year change 3-year change Capi.($)
+8.16%+11.30%+264.86%+433.68% 2.27B
+0.10%+2.47%+22.89%+4.56% 212B
+1.55%+0.04%-0.44%-23.64% 137B
+5.76%+4.57%-22.80%+19.87% 125B
+3.28%+4.77%-55.35%-6.29% 69.46B
+3.18%+6.17%+10.08%+10.20% 49.56B
+6.10%+9.98%-15.42%-19.36% 47.2B
+0.63%+0.71%+20.92%+11.05% 39.08B
-0.62%+1.20%+31.54%+28.91% 37.05B
-2.85%+6.81%+105.58%+9.19% 30.97B
Average +2.42%+3.56%+36.18%+46.82% 74.98B
Weighted average by Cap. +1.81%+2.81%+4.98%+2.84%

Financials

2026 *2027 *
Net sales 280M 243M 227M 208M 393M 26.64B 399M 2.67B 1.05B 13.29B 1.05B 1.03B 43.82B 331M 288M 269M 247M 465M 31.57B 473M 3.17B 1.24B 15.74B 1.24B 1.22B 51.92B
Net income -24.77M -21.52M -20.09M -18.45M -34.78M -2.36B -35.39M -237M -92.8M -1.18B -93.02M -90.96M -3.88B 2.62M 2.28M 2.13M 1.95M 3.68M 250M 3.75M 25.08M 9.82M 125M 9.85M 9.63M 411M
Net Debt - -
Logo Axogen, Inc.
Axogen, Inc. is focused on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. It offers repair solutions for surgeons and healthcare providers. Its portfolio of products includes Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard HA+ Nerve Protector, Axoguard Nerve Cap, and Avive+ Soft Tissue Matrix. Avance Nerve Graft is a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves. The Axoguard Nerve Connector is a porcine (pig) submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves. Axoguard Nerve Protector is a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments. Axoguard HA+ Nerve Protector consists of a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel.
Employees
622
Date Price Change Volume
03/08/26 US$45.72 +8.30% 708,701
31/07/26 US$42.21 +2.08% 1,223,566
30/07/26 US$41.35 -0.05% 1,394,655
29/07/26 US$41.37 +0.53% 2,509,782
28/07/26 US$41.15 +0.02% 1,365,319
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
42.21USD
Average target price
53.22USD
Spread / Average Target
+26.09%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AXGN Stock